- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Volume is elevated versus the 13-week average, confirming attention.
SNN
NYSE
Week ended 31 Jul 2026
Weekly Investor Report
Smith & Nephew SNATS Inc · Healthcare · Medical Devices
Latest close
31.56 USD
3.2%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -1.4% below the Trend Line and sits at 32.2% of its 52-week range. The latest completed week returned 3.2%, after a 4.3% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers. Options positioning is bearish with 58/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: earnings are due in 2d.
Setup score
45
out of 100
Latest Close
31.56 USD
31 Jul 2026
1W Return
3.2%
latest completed week
4W Return
4.3%
short-term follow-through
12W Return
5.4%
quarterly tape
Trend Breadth
34.6%
18 of 52 weeks active
Volume Ratio
1.6x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.2%
Latest completed week; four-week move 4.3%.
Indicator stack
19/63
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Options pressure
Bearish
58/100 conviction; expected move 7.8%.
News sentiment
56/100
56 relevant articles in the latest sentiment read.
Event risk
2d
Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -1.4% below the Trend Line and sits at 32.2% of its 52-week range. The latest completed week returned 3.2%, after a 4.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0912-week average 0.14
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure1/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.09Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 4.3% over four weeks, 5.4% over 12 weeks, and 4.8% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year18
Trend breadth34.6%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.17Latest activity-pressure read.
Pressure change126.9%Four-week change in activity pressure.
Leadership-12.67Latest relative-leadership reading.
RS change25.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 100%
Model confidence 82%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength90/100Blend of value, momentum, and quality. Underlying universe rank 11; rank 1 is best.
Value89/100Relative valuation strength. Underlying universe rank 12; rank 1 is best.
Quality98/100Profitability and accounting quality. Underlying universe rank 3; rank 1 is best.
Momentum26/100Medium-term price momentum. Underlying universe rank 75; rank 1 is best.
Growth95/100Revenue and earnings growth. Underlying universe rank 6; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework90/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 12.4x Price divided by trailing earnings.
- Price / sales
- 1.1x Market value relative to trailing revenue.
- EV / EBITDA
- 5.6x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 19.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 68.8% Gross profit retained from each unit of revenue.
- Operating margin
- 13.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 25.8% Free cash flow generated from revenue.
- Return on invested capital
- 16.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 43.2% Latest one-year revenue growth.
- EPS growth
- 149.9% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 109.1% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 7/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 2.6% Cash dividends relative to market value.
- Buyback yield
- 3.8% Net share repurchases relative to market value.
- Shareholder yield
- 6.4% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningBearish
SNN shows bearish options pressure with a 58/100 conviction score, put-call volume ratio of n/a, expected move of 7.8%, and Sharemaestro trend signal inactive.
Conviction58/100
Expected move7.8%
Put/call volume
Insider activity-
No recent insider transactions are stored for this company.
News sentiment56/100
Weighted news tone is neutral across 56 relevant articles.
17 positive · 38 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move7.8%Nearest-chain priced movement where available.
52-week drawdown-16.7%Distance below the 52-week high.
13-week volatility2.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher12 of 2614 weeks finished lower.
Best week+4.3%Week of 13 Feb.
Worst week-8.1%Week of 24 Apr.
Latest week+3.2%Week of 31 Jul.
Shape of recent returns
Strong gains2
Modest gains10
Flat weeks0
Modest losses12
Sharp losses2
Recent vol2.2%13-week weekly-return volatility.
Base vol3.8%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew2.5% / -2.6%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank25 / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Medical Devices
4-week rank28 / 100
Group average-2.3%
Trend breadth36.0%
Trend36.0%active weekly trend signals
MD67.0%positive activity pressure
RS29.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape40/100
Trend, activity pressure, participation, and risk combine to a 40/100 tape read.
Indicator analysis12/100Latest 12-week confirmation: trend 0/12, activity pressure 1/12, relative leadership 0/12.
Activity pressure 0.09; No reversal markers Factors77/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Cornerstone Growth rank 74; Buyback Yield rank 15; Small Cap Core rank 10 SVQF90/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 105.5 of 1013 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options32/100SNN shows bearish options pressure with a 58/100 conviction score, put-call volume ratio of n/a, expected move of 7.8%, and Sharemaestro trend signal inactive.
Bearish · Put-side pressure · Expected move 7.8% Sentiment56/100Weighted news tone is neutral across 56 relevant articles.
Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation Insiders50/100No recent insider transaction evidence is stored.
Earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 31.56 USD | 3.2% | 32.01 USD | 28.20 USD | 0.17 | -12.67 | 11.8M | Off |
| 24 Jul 2026 | 30.57 USD | -0.1% | 32.03 USD | 28.16 USD | -0.15 | -14.71 | 6.9M | Off |
| 17 Jul 2026 | 30.59 USD | -0.4% | 32.10 USD | 28.15 USD | -0.20 | -15.42 | 10.9M | Off |
| 10 Jul 2026 | 30.70 USD | 1.5% | 32.16 USD | 28.14 USD | -0.46 | -16.63 | 6.3M | Off |
| 3 Jul 2026 | 30.25 USD | 0.7% | 32.21 USD | 28.12 USD | -0.61 | -16.97 | 8.7M | Off |
| 26 Jun 2026 | 30.04 USD | -0.1% | 32.30 USD | 28.11 USD | -0.75 | -16.00 | 6.6M | Off |
| 19 Jun 2026 | 30.08 USD | -1.6% | 32.39 USD | 28.10 USD | -0.92 | -18.12 | 4.3M | Off |
| 12 Jun 2026 | 30.57 USD | -0.1% | 32.47 USD | 28.10 USD | -0.93 | -16.26 | 5.0M | Off |
| 5 Jun 2026 | 30.61 USD | 3.1% | 32.52 USD | 28.09 USD | -0.98 | -15.92 | 7.5M | Off |
| 29 May 2026 | 29.69 USD | -2.8% | 32.59 USD | 28.07 USD | -0.98 | -20.75 | 4.5M | Off |
| 22 May 2026 | 30.53 USD | 3.4% | 32.81 USD | 28.06 USD | -0.82 | -17.62 | 5.4M | Off |
| 15 May 2026 | 29.54 USD | -1.4% | 33.00 USD | 28.04 USD | -0.65 | -19.84 | 5.6M | Off |
| 8 May 2026 | 29.95 USD | -3.9% | 33.21 USD | 28.04 USD | -0.39 | -18.81 | 9.4M | Off |
| 1 May 2026 | 31.16 USD | -1.3% | 33.36 USD | 28.04 USD | -0.20 | -13.84 | 6.3M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.